INHIBITION OF TUMOR PROMOTER-MEDIATED OXIDATIVE PROCESSES BY CAFFEIC ACID PHENETHYL ESTER (CAPE) (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

INHIBITION OF TUMOR PROMOTER-MEDIATED OXIDATIVE PROCESSES BY CAFFEIC ACID PHENETHYL ESTER (CAPE) (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A967 1992. Unique Identifier : AIDSLINE ICDB/92683493
Frenkel K; Wei H; Bhimani R; Ye J; Huang MT; Ferraro T; Conney AH; Grunberger D; Dept. of Environmental Medicine, New York Univ. Medical Center,; New York, NY 10016

Abstract: CAPE, a product isolated from the propolis of honey-bee hives, is cytotoxic to tumor and virally transformed, but not to normal cells. However, its mode of action is unknown. Since tumor promoters induce oxidative processes in vitro and in vivo, we evaluated the effect of CAPE upon these processes. We found that CAPE inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-mediated infiltration of polymorphonuclear leukocytes (PMNs), formation of H2O2 and the oxidized DNA bases 5-hydroxymethyl uracil and 8-hydroxylguanine in SENCAR mouse epidermis at 6.5 nmol, and induction of ornithine decarboxylase and edema in SENCAR and CD-1 mice at 1-10 umol. CAPE also inhibits activation of human PMNs by TPA and H2O2 production, as well as H2O2 formation by and opacity of TPA-treated bovine lenses. Hence, CAPE is a potential chemopreventive agent, which may suppress carcinogenesis by inhibiting oxidative processes that are hallmarks of tumor promotion, and potentially also prevent cataracts.

Keywords: Animal Antineoplastic Agents/*PHARMACOLOGY Caffeic Acids/*PHARMACOLOGY Carcinogens/*PHARMACOLOGY Cattle DNA Damage Edema/PREVENTION & CONTROL Esters Human Hydrogen Peroxide/METABOLISM Lens, Crystalline/DRUG EFFECTS/PATHOLOGY Mice Mice, Inbred Strains Neutrophils/DRUG EFFECTS/PHYSIOLOGY Ornithine Decarboxylase/BIOSYNTHESIS Tetradecanoylphorbol Acetate/*PHARMACOLOGY/TOXICITY ABSTRACT
920830
M9281094

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .